English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Objectives: This study aimed to compare the efficacy of the α-interferon treatment with α-interferon plus lamivudine for cases of chronic hepatitis B. Materials and methods: Sixty-one HBeAg negative naive chronic hepatitis B patients were randomly evaluated in two groups prospectively. In group 1, 30 patients were simultaneously given α-interferon 2a 9 MU, 3 days a week by s.c. injection plus lamivudine 100 mg a day for 12 months. In group II, there were 31 patients who only was received the same dosage of α-interferon and no lamivudine over the same period of time. Results: In group 1 the initial mean value of alanine aminotransferase (ALT) was 144±59 IU/L and decreased to 38.8±19.3 IU/L; in group II, initial mean values of ALT was 141±52 IU/L and decreased to 53.2±14.7 IU/L at the end of 12th month of the therapy (P<0.05). Hepatitis B virus DNA (HBV-DNA) clearance was obtained in 13 of 30 patients (43.3%) in group I patients and 15 of 31 (48.4%) in group II at the end of the therapy (p=0.692). The number of patients with complete response was found to be 14 out of 30 (48.4%) in group 1 and 15 out of 31 cases (46.7%) in group II, six months after the end of the therapy (P=0.893). Conclusion: α-interferon and lamivudine combination therapy had a more beneficial effect than α-interferon monotherapy in normalization of ALT and clearance of HBV-DNA; however, the complete response rate at 6 months after the end of the therapy was not statistically significantly different between both groups. J Microbiol Infect Dis 2011;1(2): 58-63

Comparison of lamivudine - α-interferon combination and α-interferon alone treatments in adult patients with naive HBeAg negative hepatitis B